Participated · Series B · Oct 2025

Founded in 2015 by Jogin Desai, Rajani Battu, and Rajarshi Pal, Eyestem is focused on cell replacement therapies for retinal disorders. Its lead candidate, Eyecyte-RPE, aims to treat dry age-related macular degeneration by using retinal pigment epithelium cells derived from human stem cells to restore damaged retinal tissue. The company remains in the pre-revenue stage and generated Rs 2.92 crore in non-operating income during FY24 while reporting a net loss of Rs 12.18 crore. Post-money, Eyestem’s valuation has risen roughly 70% to Rs 592 crore (about $67 million). To date, the firm has raised roughly $20 million, including a $6.4 million Series A in August 2022. Major external shareholders now include Jacesa Investments (12.5%), Cytespace (9.64%), and Endiya Partners (7.12%), while the co-founders collectively hold 21.19%. The fresh capital is expected to advance clinical development and expand the company’s pipeline of regenerative eye treatments.

Participated · Seed · Mar 2022

Zapkey offers guaranteed home sales: if a listed property doesn't sell within three months the company purchases it. Its pricing is driven by proprietary algorithms that analyze over 30 lakh property registration records to ensure fair market pricing and transparency. Founded in 2020 by Shubhankar Dongre, Sandeep Reddy and Raja Seetharaman, the company launched an initial program in Thane (Mumbai). Zapkey plans to use new funding to strengthen its technology and operations teams and aims to close deals on over a hundred apartments in the next 3–4 months, supported by a credit line. The company’s stated vision is to bring liquidity, trust and transparent pricing to the large resale home market, which the article cites as over a USD 50 billion opportunity with roughly 300,000 resale homes exchanging hands annually in the top seven cities.